{"pmid":32279352,"title":"Blood and blood product use during COVID-19 Infection.","text":["Blood and blood product use during COVID-19 Infection.","Am J Hematol","Fan, Bingwen Eugene","Ong, Kiat Hoe","Chan, Stephrene Seok Wei","Young, Barnaby Edward","Chong, Vanessa Cui Lian","Chen, Siew Ping Connie","Lim, Shu Ping","Lim, Geok Ping","Kuperan, Ponnudurai","32279352"],"journal":"Am J Hematol","authors":["Fan, Bingwen Eugene","Ong, Kiat Hoe","Chan, Stephrene Seok Wei","Young, Barnaby Edward","Chong, Vanessa Cui Lian","Chen, Siew Ping Connie","Lim, Shu Ping","Lim, Geok Ping","Kuperan, Ponnudurai"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32279352","week":"202016|Apr 13 - Apr 19","doi":"10.1002/ajh.25823","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1663890921985409024,"score":7.9164424,"similar":[{"pmid":32267830,"title":"Blood transfusion during the COVID-19 outbreak.","text":["Blood transfusion during the COVID-19 outbreak.","Blood Transfus","Cai, Xiaohong","Ren, Ming","Chen, Fenghua","Li, Liliang","Lei, Hang","Wang, Xuefeng","32267830"],"journal":"Blood Transfus","authors":["Cai, Xiaohong","Ren, Ming","Chen, Fenghua","Li, Liliang","Lei, Hang","Wang, Xuefeng"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267830","week":"202015|Apr 06 - Apr 12","doi":"10.2450/2020.0076-20","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1663609715732512769,"score":74.57695},{"pmid":32220179,"title":"[The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19].","text":["[The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19].","Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients.","Sichuan Da Xue Xue Bao Yi Xue Ban","Ma, Wan-Xia","Ran, Xing-Wu","32220179"],"abstract":["Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients."],"journal":"Sichuan Da Xue Xue Bao Yi Xue Ban","authors":["Ma, Wan-Xia","Ran, Xing-Wu"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220179","week":"202013|Mar 23 - Mar 29","doi":"10.12182/20200360606","keywords":["Blood glucose level","Blood glucose monitoring","Coronavirus disease 2019, COVID-19","Diabetes mellitus","Inpatient glycemic control","Insulin","Therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Blood Glucose"],"_version_":1663352135093321728,"score":62.59999},{"pmid":32279346,"title":"Morphological anomalies of circulating blood cells in COVID-19.","text":["Morphological anomalies of circulating blood cells in COVID-19.","In patients with COIVD-19, in the early aggravation phase before treatment, observation of peripheral blood film shows the presence of pronounced morhological anomalies of the granulocyte series. One week after the start of treatment, such anomalies subside, and an increasing proportion of reactive lymphocytes dominates. This article is protected by copyright. All rights reserved.","Am J Hematol","Zini, Gina","Bellesi, Silvia","Ramundo, Francesco","d'Onofrio, Giuseppe","32279346"],"abstract":["In patients with COIVD-19, in the early aggravation phase before treatment, observation of peripheral blood film shows the presence of pronounced morhological anomalies of the granulocyte series. One week after the start of treatment, such anomalies subside, and an increasing proportion of reactive lymphocytes dominates. This article is protected by copyright. All rights reserved."],"journal":"Am J Hematol","authors":["Zini, Gina","Bellesi, Silvia","Ramundo, Francesco","d'Onofrio, Giuseppe"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32279346","week":"202016|Apr 13 - Apr 19","doi":"10.1002/ajh.25824","source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1663890922040983552,"score":62.59999},{"pmid":32270880,"title":"Coronavirus-19 Disease (COVID-19) and Decrease in Blood Donation: Experience of Iranian Blood Transfusion Organization (IBTO).","text":["Coronavirus-19 Disease (COVID-19) and Decrease in Blood Donation: Experience of Iranian Blood Transfusion Organization (IBTO).","According to the World Health Organization (00:00CET 19 March 2020), coronavirus disease 2019 (COVID-19), has invaded up to 150 countries/territories. With 17,361 confirmed cases and 1135 deaths, after China and Italy, Iran is the 3rd most affected country in the world and the first one in the Eastern Mediterranean Region [1].","Vox Sang","Mohammadi, Saeed","Tabatabaei Yazdi, Seyed Morteza","Eshghi, Peyman","Norooznezhad, Amir Hossein","32270880"],"abstract":["According to the World Health Organization (00:00CET 19 March 2020), coronavirus disease 2019 (COVID-19), has invaded up to 150 countries/territories. With 17,361 confirmed cases and 1135 deaths, after China and Italy, Iran is the 3rd most affected country in the world and the first one in the Eastern Mediterranean Region [1]."],"journal":"Vox Sang","authors":["Mohammadi, Saeed","Tabatabaei Yazdi, Seyed Morteza","Eshghi, Peyman","Norooznezhad, Amir Hossein"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32270880","week":"202015|Apr 06 - Apr 12","doi":"10.1111/vox.12930","source":"PubMed","locations":["China","Iran","Italy"],"countries":["Iran, Islamic Republic of","China","Italy"],"countries_codes":["IRN|Iran, Islamic Republic of","CHN|China","ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1663620082996084736,"score":61.88634},{"pmid":32147378,"title":"COVID-19 and Blood Safety: Help with a Dilemma.","text":["COVID-19 and Blood Safety: Help with a Dilemma.","Transfus Med Rev","Dodd, Roger Y","Stramer, Susan L","32147378"],"journal":"Transfus Med Rev","authors":["Dodd, Roger Y","Stramer, Susan L"],"date":"2020-03-10T11:00:00Z","year":2020,"_id":"32147378","week":"202011|Mar 09 - Mar 15","doi":"10.1016/j.tmrv.2020.02.004","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663352134146457603,"score":60.65286}]}